ORKA Oruka Therapeutics Inc Forecast, Technical & Fundamental Analysis
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications... Show more
ORKA is expected to report earnings to rise 13.89% to -51 cents per share on August 17
Q2'26
Est.
$-0.51
Q4'25
Beat
by $0.27
Q3'25
Beat
by $0.01
Q2'25
Beat
by $0.20
Q1'25
Beat
by $0.04
The last earnings report on March 12 showed earnings per share of -44 cents, beating the estimate of -72 cents. With 119.81K shares outstanding, the current market capitalization sits at 5.91B.
A.I.dvisor indicates that over the last year, ORKA has been loosely correlated with SYRE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ORKA jumps, then SYRE could also see price increases.
Aroon Indicator for ORKA shows an upward move is likely
ORKA's Aroon Indicator triggered a bullish signal on July 10, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 187 similar instances where the Aroon Indicator showed a similar pattern. In of the 187 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 17, 2026. You may want to consider a long position or call options on ORKA as a result. In of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ORKA just turned positive on August 04, 2026. Looking at past instances where ORKA's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for ORKA moved out of overbought territory on July 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORKA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ORKA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.210) is normal, around the industry mean (20.076). P/E Ratio (0.000) is within average values for comparable stocks, (25.135). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.546). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (412.299).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORKA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
